| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Lexaria Bioscience Corp. | Chief Executive Officer, Director | Stock Options | 350K | $427K | $1.22 | Jul 29, 2025 | Direct |
| Lexaria Bioscience Corp. | Chief Executive Officer, Director | common shares | 65K | $59.1K | $0.91 | Jul 29, 2025 | Direct |
| INVIVO THERAPEUTICS HOLDINGS CORP. | Chief Financial Officer | Stock Option (right to buy) | 20.8K | Nov 17, 2022 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| LEXX | Lexaria Bioscience Corp. | Jul 29, 2025 | 1 | $13.6K | 4 | Jul 30, 2025 | Chief Executive Officer, Director |
| LEXX | Lexaria Bioscience Corp. | May 15, 2025 | 1 | $0 | 4 | May 16, 2025 | Chief Executive Officer, Director |
| LEXX | Lexaria Bioscience Corp. | Dec 2, 2024 | 2 | $118K | 4 | Dec 3, 2024 | Chief Executive Officer |
| LEXX | Lexaria Bioscience Corp. | Aug 31, 2024 | 0 | $0 | 3 | Sep 5, 2024 | Chief Executive Officer |
| NVIV | INVIVO THERAPEUTICS HOLDINGS CORP. | Nov 17, 2022 | 1 | $0 | 4 | Nov 21, 2022 | Chief Financial Officer |